ACE Polymorphism and Cardiovascular Risk | Decoding Inflammation

By Alberto Rivera, MD · 2026-06-16 · 3 min read

The ACE Insertion/Deletion (I/D) Polymorphism\n\nThe Angiotensin-Converting Enzyme (ACE) gene plays a central role in the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and fluid balance. However, its implications extend far beyond simple hemodynamics. The most studied variant is the Insertion/Deletion (I/D) polymorphism in intron 16. Individuals homozygous for the D allele (DD genotype) exhibit significantly higher plasma and tissue ACE concentrations—up to twice the levels—compared to those with the II genotype. This elevation in ACE activity results in an overproduction of Angiotensin II (Ang II), a potent pro-inflammatory mediator, while simultaneously increasing the degradation of bradykinin, a vasodilator with anti-inflammatory properties.\n\n## Angiotensin II as a Pro-inflammatory Cytokine\n\nAng II is not merely a vasoconstrictor; it acts as a primary driver of vascular inflammation. By binding to Angiotensin II type 1 (AT1) receptors, it stimulates the production of reactive oxygen species (ROS) via the activation of NADPH oxidase. This oxidative stress triggers the nuclear factor-kappa B (NF-κB) pathway, leading to the expression of pro-inflammatory cytokines such as IL-6, TNF-α, and monocyte chemoattractant protein-1 (MCP-1). For the DD genotype, this chronic upregulation of the RAAS creates a persistent pro-inflammatory state within the vascular endothelium. This 'leaky' and inflamed endothelium facilitates the infiltration of low-density lipoproteins (LDL) and immune cells, predisposing patients to accelerated atherosclerosis, myocardial infarction, and hypertension-related end-organ damage.\n\n## Clinical Implications and Targeted Management\n\nIn a precision medicine framework, identifying a patient's ACE genotype allows for more aggressive management of cardiovascular risk. While ACE inhibitors (ACEis) and Angiotensin II Receptor Blockers (ARBs) are standard therapies, DD genotype patients may require higher dosages or earlier intervention to suppress the exaggerated inflammatory response. Furthermore, these patients often show increased sensitivity to sodium intake, which further activates the RAAS, making stringent dietary interventions critical. From a genomic perspective, the ACE DD polymorphism represents a high-risk inflammatory marker that necessitates a multifaceted approach combining pharmacotherapy, lifestyle modification, and continuous monitoring of inflammatory biomarkers like hs-CRP to mitigate long-term cardiovascular decay.